Atypical antipsychotics have replaced conventional antipsychotics in the treatment of schizophrenia because they have less of a propensity to cause undesirable neurologic adverse events including extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome (NMS). However, atypical antipsychotics have been known to result in various metabolic complications such as impaired glucose tolerance, diabetes and even diabetic ketoacidosis (DKA). In addition, a number of NMS cases have been reported in patients treated with atypical antipsychotics, although the absolute incidence of neurologic side effects is currently significantly low. Here, we report a patient who simultaneously developed DKA, acute renal failure and NMS with rhabdomyolysis after olanzapine treatment. Olanzapine-induced metabolic complications and NMS were dramatically improved with cessation of the olanzapine treatment and initiation of supportive management including fluid therapy, hemodialysis, and intensive glycemic control using insulin. At short-term follow-up, insulin secretion was markedly recovered as evidenced by a restoration of serum C-peptide level, and the patient no longer required any hypoglycemic medications. Despite the dramatic increase in the use of atypical antipsychotics treatment, individualized treatments along with careful monitoring may be prudent for high risk or vulnerable patients in order to avoid the development of metabolic side effects.

Citations

Citations to this article as recorded by  

• Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report
  Francesco Piacenza, Suet Kee Ong, Patrick O’Brien, Maurice Clancy
  Clinical Case Reports.2021; 9(4): 2404.     CrossRef
• Succinylcholine-Induced Rhabdomyolysis in Adults: Case Report and Review of the Literature
  Robert William Barrons, Liem T. Nguyen
  Journal of Pharmacy Practice.2020; 33(1): 102.     CrossRef
• Improvement in renal prognosis with prompt hemodialysis in hyperosmolar hyperglycemic state-related rhabdomyolysis
  I-Wen Chen, Cheng-Wei Lin
  Medicine.2018; 97(50): e13647.     CrossRef
• Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication
  Antonia Vuk, Maja Baretic, Martina Matovinovic Osvatic, Igor Filipcic, Nikolina Jovanovic, Martina Rojnic Kuzman
  Journal of Clinical Psychopharmacology.2017; 37(5): 584.     CrossRef
• A Case of Primary Hypoparathyroidism Presenting with Acute Kidney Injury Secondary to Rhabdomyolysis
  Abdullah Sumnu, Zeki Aydin, Meltem Gursu, Sami Uzun, Serhat Karadag, Egemen Cebeci, Savas Ozturk, Rumeyza Kazancioglu
  Case Reports in Nephrology.2016; 2016: 1.     CrossRef
• Nanoneurotherapeutics approach intended for direct nose to brain delivery
  Shadab Md, Gulam Mustafa, Sanjula Baboota, Javed Ali
  Drug Development and Industrial Pharmacy.2015; 41(12): 1922.     CrossRef
• Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
  Won-Young Lee
  Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef